NeuroCytonix's technology has shown to be effective in treating patients suffering from incurable neurological disorders
NASSAU, Bahamas, March 2, 2023 /PRNewswire-PRWeb/ -- NeuroCytonix, Bahamas (the "Company" or "NeuroCytonix") today announced that it is launching a $12 million Active Managed Certificate (AMC) capital raise from non-US investors to finance the creation of a neurological rehabilitation center in The Bahamas that will use NeuroCytonix brain tissue regeneration technology.
UCAP BAHAMAS (Capital Union Bank Group) and YorkCap are NeuroCytonix bankers for the transaction.
NeuroCytonix has developed a new technology that has shown to be effective in treating patients suffering from Cerebral Palsy, Stroke, Traumatic Brain Injury (TBI) and Covid 19 neurological issues in brief non degenerative brain diseases. Please see http://www.neurocytonix.com for more information.
About NeuroCytonix Bahamas:
NeuroCytonix Bahamas is part of the NeuroCytonix Group that is an emerging biotechnology business founded in January 2017 to develop and exploit transformational medical technologies for the regeneration of the nervous system. The Company's technology and related protocols include Stroke, Autism, Cerebral Palsy and neurological consequences of Traumatic Brain Injury (TBI) and Covid 19. The Company's core technology, the NEUROCYTOTRON, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins which aid in the regeneration of brain cells.
NeuroCytonix Bahamas will open a high-end neurological rehabilitation center that will support patients from the Caribbean, US and Europe suffering from various forms of neurological pathologies.
NeuroCytonix has built a Research Center in Monterrey Mexico where it has trained and directed a clinical research team who has successfully implemented its first Cerebral Palsy clinical trial evaluating the safety and efficacy of the treatment. An approval from the Mexican regulator COFEPRIS has been issued in January 2023.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact
Stephane Cathelin – Director- NeuroCytonix Bahamas
[email protected]
Media Contact
Stephane Cathelin, NeuroCytonix Bahamas, 1 929-476-6690, [email protected]
SOURCE NeuroCytonix Bahamas
Share this article